Preoperative CA 19-9 Predicts Disease Progression in Colorectal Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy : An Analysis from the US HIPEC Collaborative
© 2024. Society of Surgical Oncology..
INTRODUCTION: Patients with colorectal peritoneal metastases (CRPM) are increasingly treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC). Unfortunately, data identifying preoperative risk factors for poor oncologic outcomes after this procedure are limited. We aimed to determine the prognostic value of preoperative CEA, CA 125, and CA 19-9 on disease progression after CRS/HIPEC.
METHODS: Patients with CRPM treated with curative intent CRS/HIPEC from 12 participating sites in the United States from 2000 to 2017 were identified. Progression-free survival (PFS), defined as disease progression or recurrence, was the primary outcome.
RESULTS: In 279 patients who met inclusion criteria, the rate of disease progression was 63.8%, with a median PFS of 11 months (interquartile range [IQR] 5-20). Elevated CA 19-9 was associated with dismal PFS at 2 years (8.9% elevated vs. 30% not elevated, p < 0.01). In 113 patients who underwent upfront CRS/HIPEC, CA 19-9 emerged as the sole tumor marker independently predictive of worse PFS (hazard ratio [HR] 2.88, p = 0.048). In the subgroup of patients who had received neoadjuvant therapy (NAT), no variable was independently predictive of PFS. CA 19-9 levels over 37 U/ml were highly specific for accelerated disease progression after CRS/HIPEC. Lastly, there was no association between PFS and elevated CEA or CA 125.
CONCLUSIONS: Elevated CA 19-9 is associated with decreased PFS in patients with CRPM. While traditionally CEA is the main tumor marker assessed in colon cancer, we found that CA 19-9 may better inform preoperative risk stratification for poor oncologic outcomes in patients with CRPM. However, prospective studies are required to confirm this association.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:31 |
|---|---|
| Enthalten in: |
Annals of surgical oncology - 31(2024), 5 vom: 02. Apr., Seite 3314-3324 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Fackche, Nadege T [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 10.04.2024 Date Revised 10.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1245/s10434-024-14890-0 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367996596 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367996596 | ||
| 003 | DE-627 | ||
| 005 | 20240410232454.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240204s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1245/s10434-024-14890-0 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1371.xml |
| 035 | |a (DE-627)NLM367996596 | ||
| 035 | |a (NLM)38310181 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Fackche, Nadege T |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Preoperative CA 19-9 Predicts Disease Progression in Colorectal Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy |b An Analysis from the US HIPEC Collaborative |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.04.2024 | ||
| 500 | |a Date Revised 10.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. Society of Surgical Oncology. | ||
| 520 | |a INTRODUCTION: Patients with colorectal peritoneal metastases (CRPM) are increasingly treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC). Unfortunately, data identifying preoperative risk factors for poor oncologic outcomes after this procedure are limited. We aimed to determine the prognostic value of preoperative CEA, CA 125, and CA 19-9 on disease progression after CRS/HIPEC | ||
| 520 | |a METHODS: Patients with CRPM treated with curative intent CRS/HIPEC from 12 participating sites in the United States from 2000 to 2017 were identified. Progression-free survival (PFS), defined as disease progression or recurrence, was the primary outcome | ||
| 520 | |a RESULTS: In 279 patients who met inclusion criteria, the rate of disease progression was 63.8%, with a median PFS of 11 months (interquartile range [IQR] 5-20). Elevated CA 19-9 was associated with dismal PFS at 2 years (8.9% elevated vs. 30% not elevated, p < 0.01). In 113 patients who underwent upfront CRS/HIPEC, CA 19-9 emerged as the sole tumor marker independently predictive of worse PFS (hazard ratio [HR] 2.88, p = 0.048). In the subgroup of patients who had received neoadjuvant therapy (NAT), no variable was independently predictive of PFS. CA 19-9 levels over 37 U/ml were highly specific for accelerated disease progression after CRS/HIPEC. Lastly, there was no association between PFS and elevated CEA or CA 125 | ||
| 520 | |a CONCLUSIONS: Elevated CA 19-9 is associated with decreased PFS in patients with CRPM. While traditionally CEA is the main tumor marker assessed in colon cancer, we found that CA 19-9 may better inform preoperative risk stratification for poor oncologic outcomes in patients with CRPM. However, prospective studies are required to confirm this association | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Biomarkers, Tumor |2 NLM | |
| 700 | 1 | |a Schmocker, Ryan K |e verfasserin |4 aut | |
| 700 | 1 | |a Nudotor, Richard |e verfasserin |4 aut | |
| 700 | 1 | |a Kubi, Boateng |e verfasserin |4 aut | |
| 700 | 1 | |a Cloyd, Jordan M |e verfasserin |4 aut | |
| 700 | 1 | |a Grotz, Travis E |e verfasserin |4 aut | |
| 700 | 1 | |a Fournier, Keith F |e verfasserin |4 aut | |
| 700 | 1 | |a Dineen, Sean P |e verfasserin |4 aut | |
| 700 | 1 | |a Veerapong, Jula |e verfasserin |4 aut | |
| 700 | 1 | |a Baumgartner, Joel M |e verfasserin |4 aut | |
| 700 | 1 | |a Clarke, Callisia N |e verfasserin |4 aut | |
| 700 | 1 | |a Patel, Sameer H |e verfasserin |4 aut | |
| 700 | 1 | |a Wilson, Gregory C |e verfasserin |4 aut | |
| 700 | 1 | |a Lambert, Laura A |e verfasserin |4 aut | |
| 700 | 1 | |a Pokrzywa, Courtney |e verfasserin |4 aut | |
| 700 | 1 | |a Abbott, Daniel E |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Byrne |e verfasserin |4 aut | |
| 700 | 1 | |a Staley, Charles A |e verfasserin |4 aut | |
| 700 | 1 | |a Zaidi, Mohammad Y |e verfasserin |4 aut | |
| 700 | 1 | |a Johnston, Fabian M |e verfasserin |4 aut | |
| 700 | 1 | |a Greer, Jonathan B |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of surgical oncology |d 1995 |g 31(2024), 5 vom: 02. Apr., Seite 3314-3324 |w (DE-627)NLM074734997 |x 1534-4681 |7 nnns |
| 773 | 1 | 8 | |g volume:31 |g year:2024 |g number:5 |g day:02 |g month:04 |g pages:3314-3324 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1245/s10434-024-14890-0 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 31 |j 2024 |e 5 |b 02 |c 04 |h 3314-3324 | ||